In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 47 days of free consultation


Impact of guideline-recommended medical therapy at discharge on long-term mortality in patients with or without left ventricular dysfunction after primary PCI for STEMI

Session Challenges in contemporary management of coronary artery disease

Speaker Dejan Milacinovic

Congress : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Systolic Ventricular Dysfunction
  • Session type : Moderated Posters
  • FP Number : P5011

Authors : M Radomirovic (Belgrade,RS), D Milasinovic (Belgrade,RS), Z Mehmedbegovic (Belgrade,RS), D Jelic (Belgrade,RS), V Zobenica (Belgrade,RS), S Zaharijev (Belgrade,RS), I Zivkovic (Belgrade,RS), A Pavlovic (Belgrade,RS), J Dudic (Belgrade,RS), A Obreski (Belgrade,RS), A Dolicanin (Belgrade,RS), V Vukcevic (Belgrade,RS), M Asanin (Belgrade,RS), G Stankovic (Belgrade,RS)

M Radomirovic1 , D Milasinovic1 , Z Mehmedbegovic1 , D Jelic1 , V Zobenica1 , S Zaharijev1 , I Zivkovic1 , A Pavlovic1 , J Dudic1 , A Obreski1 , A Dolicanin1 , V Vukcevic1 , M Asanin1 , G Stankovic1 , 1Clinical Center of Serbia, Clinic for Cardiology - Belgrade - Serbia ,


BACKGROUND: Clinical practice guidelines provide class I recommendation for the use of angiotensin-converting enzyme inhibitors (ACE-I) and beta-blockers in patients with prior myocardial infarction and left ventricular (LV) dysfunction, whereas their use in patients without LV dysfunction is considered to be a class IIa recommendation.

PURPOSE: Our aim was to comparatively assess the impact of ACE-I and/or beta-blockers on 3-year mortality in patients with or without impaired left ventricular (LV) function undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

METHODS: The analysis included 4425 patients admitted for primary PCI during 2009 – 2015 from a prospective, electronic registry of a high-volume tertiary center, who survived initial hospitalization, and for whom information on LV function and discharge medication were available. Patients were stratified according to LV systolic dysfunction, defined as LVEF <40%. Unadjusted and adjusted Cox regression models were created to investigate the impact of beta-blocker and/or ACE-I therapy on 3-year mortality.

RESULTS: 22.9% (n=1013) had LV dysfunction, 23.0% (n=1017) received either an ACE-I or a beta-blocker and 72.2% received both medications at discharge (n=3197). The concurrent use of both ACE-I and beta-blockers was not different in LVEF=40% vs. LVEF<40% (72.4% vs. 71.7%, p=0.43). The use of at least one of the guideline-recommended medications was associated with a significantly lower 3-year mortality in both patients with LVEF=40% (18.7% if neither was used, 11.2% if either a beta-blocker or an ACE-I were used and 9.4% if both were used, p=0.001), and LVEF<40% (55.4% if neither was used, 32.5% if either a beta-blocker or an ACE-I were used and 22.9% if both were used, p<0.001) (Figure). After adjusting for significant mortality predictors including older age, diabetes, hypertension, renal failure, previous stroke, Killip class =2 and non-culprit chronic total occlusion (CTO), the concurrent use of both a beta-blocker and an ACE-I remained independently associated with lower 3-year mortality in both patients with LVEF<40% (HR 0.30, p<0.001) and LVEF=40% (HR=0.41, p=0.001). The use of a single agent was independently associated with lower mortality in patients with LVEF<40% (HR 0.45, p=0.002), but not in patients with LVEF=40% (HR 0.61, p=0.07).

CONCLUSIONS: Guideline-recommended use of both a beta-blocker and an ACE-I in post-MI patients was associated with a lower 3-year mortality regardless of the LV function, whereas using only one of the two agents was associated with improved prognosis only in patients with LV dysfunction, but not in patients without LV impairment.

This content is currently on FREE ACCESS, enjoy another 47 days of free consultation


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are